Novolog vs. Fiasp Insulin in Non-critically Ill Hospitalized Patients With Type 2 Diabetes Mellitus
Status:
Recruiting
Trial end date:
2022-02-01
Target enrollment:
Participant gender:
Summary
Hyperglycemia affects 30-40% of hospitalized patients. Despite the fact that basal/bolus
insulin therapy has been demonstrated to improve glycemic control and clinical outcomes in
patients, achieving good glucose control remains a challenge.
This study examines the effects of Fiasp (a faster acting insulin) on blood sugars after
meals compared to another type of insulin known as Novolog. The study will be performed in
patients with type 2 diabetes admitted to the hospital, who are not in the intensive care
unit, and who are being seen by the inpatient diabetes consult team. Eligible participants
will be treated with Fiasp or Novolog injected multiple times a day before meals and at
bedtime, in addition to a once daily injection of insulin glargine as basal insulin. Which
type of meal time insulin (Fiasp vs Novolog) the subject gets is decided by chance, like the
flip of a coin. Insulin doses will be started and titrated based on a protocol. All the
subjects will wear a blinded continuous glucose monitoring (CGM)) sensor placed in their arm
which they will wear for 72 hours during the study. The glucose values from the CGM,
collected during the time it is worn, will be downloaded and compared to assess the response
to the two different types of insulins - Fiasp and Novolog. The goal is to determine if Fiasp
works as well as or better than Novolog in controlling blood sugars, particularly after
meals, in the subjects of the study.